Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Theliatinib in Advanced Solid Tumors
NCT02601248Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Oct 2012
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Theliatinib in solid tumor, sponsored by Hutchison MediPharma (HMP). Primary endpoint: Incidence of Adverse Events and Abnormal Laboratory Changes. Started Oct 2012; status: completed.
02
Drugs
Theliatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02601248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601248.